Health Condition 1: C50- Malignant neoplasm of breast
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Tata Memorial Centre, Mumbai
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients that received adjuvant radiation to the breast / chestwall and/ nodal regions 2. Treated with an unconventional fractionation regimen ( defined as dose fractionation other than 40Gy/15 fractions or 50Gy/25 fractions, delivered as 1 fractional per day and 5 fractions per week 3. Patients whose radiation treatment and planning details are available in the medical records
Exclusion criteria
Exclusion criteria: 1. Patients whose radiotherapy details are unavailable 2. Patients treated with moderate hypofractionation or conventional fractionation or multi-catheter interstitial brachytherapy for accelerated partial breast irradiation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute & late radiotherapy toxicities at 1, 2 and 5 years as per the RTOG and CTCAE v 5.0Timepoint: Acute toxicity maximum grade at 3 months & late radiotherapy toxicities at 1, 2 and 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Uptake of Ultrahypofractionated RT at the participating centres among operable breast cancer (OBC) & locally advanced breast cancer (LABC) 2. Dose constraints achieved with the unconventional fractionation regimen and their impact on the radiation induced toxicities. 3. Locoregional control, disease free survival and overall survival at 2 and 5 years post RT 4. Reasons for choosing unconventional RT dose fractionation 5. Cosmetic outcome of the treated breast using the Harvard/RTOG/ NRG Scoring system 6. Compliance to radiation treatment and overall treatment timeTimepoint: Uptake of ultrahypofractionated RT after 2017 till 2025 Disease control & survival at 2 and 5 years since the date of cancer diagnosis | — |
Countries
India
Contacts
Public ContactDr Rima Sanjay Pathak
Tata Memorial Hospital
Outcome results
None listed